STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event

Halozyme (HALO) reports Q3 2025 results; CFO transition

Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 under Item 2.02.

The company also disclosed a planned CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, after which she will depart to pursue a new professional opportunity. Halozyme has initiated a search for its next CFO.

The company stated that Ms. LaBrosse’s departure is not due to any disagreement with its independent auditors or with the company regarding financial statements, internal control over financial reporting, operations, policies, or practices. The company expects to enter into a transition and release agreement with Ms. LaBrosse.

Positive

  • None.

Negative

  • None.

Insights

Orderly CFO transition with no stated disagreements; neutral.

Halozyme announced Q3 results via a furnished press release and outlined a CFO succession plan. Nicole LaBrosse will remain CFO until a successor is appointed or until March 30, 2026, providing continuity during the transition.

The company explicitly notes her departure is not due to disagreements on financial reporting or controls, which reduces governance concern typically associated with abrupt finance leadership changes. The search for the next CFO is underway.

Actual business impact will hinge on the incoming CFO’s start date and any future strategic updates disclosed in subsequent company communications.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Halozyme (HALO) announce in its latest 8-K?
Halozyme furnished a press release with Q3 2025 financial results and announced a planned CFO transition with Nicole LaBrosse.

Who is the outgoing CFO of Halozyme (HALO) and when will she depart?
Nicole LaBrosse will continue as CFO until the earlier of a new CFO being hired or March 30, 2026, then depart to pursue a new opportunity.

How did Halozyme (HALO) provide its Q3 2025 results?
Through a press release attached as Exhibit 99.1 and furnished under Item 2.02.

Has Halozyme (HALO) begun searching for a new CFO?
Yes. The company has initiated a search to identify its next CFO.

What is Exhibit 99.1 in Halozyme’s (HALO) filing?
It is the press release dated November 3, 2025, reporting Q3 2025 financial results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FALSE000115903600011590362025-11-032025-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 3, 2025
Halo Logo updated.jpg
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
Delaware 88-0488686
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
12390 El Camino Real 92130
San Diego(Zip Code)
California
(Address of principal executive offices) 
(858) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueHALOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).         
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition.
On November 3, 2025, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Company announced today a transition plan in which Nicole LaBrosse, Senior Vice President and Chief Financial Officer (“CFO”) will continue to serve as the Company’s CFO until the earlier of when a new chief financial officer is hired, or until March 30, 2026 (the “Separation Date”) and then depart to pursue a new professional opportunity. The Company has initiated a search to identify its next CFO.
Ms. LaBrosse’s departure is not the result of any disagreement with the Company’s independent auditors or the Company on any matter relating to the Company’s financial statements, internal control over financial reporting, operations, policies or practices. The Company expects to enter into a transition and release agreement with Ms. LaBrosse.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description
99.1
Press release dated November 3, 2025
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
  Halozyme Therapeutics, Inc
(Registrant)
     
Dated:
November 3, 2025 
By:
/s/ Nicole LaBrosse
  Nicole LaBrosse
  Senior Vice President, Chief Financial Officer


Source: View Original Filing on SEC EDGAR

Keep reading

More on HALO

Trending in the feed

Open the live feed